Rapamycin rescues learning, memory in Alzheimer's mouse model

Rapamycin, a drug that keeps the immune system from attacking transplanted organs, may have another exciting use: fighting Alzheimer's disease.

Rapamycin rescued learning and memory deficits in a mouse model of Alzheimer's, a team from The University of Texas Health Science Center at San Antonio reported Tuesday (Feb. 23).

The study, in the Journal of Biological Chemistry, offers the first evidence that the drug is able to reverse Alzheimer's-like deficits in an animal model, said the senior author, Salvatore Oddo, Ph.D., assistant professor in the Department of Physiology of the UT Health Science Center San Antonio.

Tissue evidence

Rapamycin also reduced lesions in the brains of the mice, the team found. The lesions are similar to those seen in the brains of people who died with Alzheimer's.

“Our findings may have a profound clinical implication,” said Dr. Oddo, who is a member of the university's Barshop Institute for Longevity and Aging Studies. “Because rapamycin is a U.S. Food and Drug Administration-approved drug, a clinical trial using it as an anti-Alzheimer's disease therapy could be started fairly quickly.”

Last year three institutions, including the Barshop Institute, announced that rapamycin extended the life span of aged research mice at each of the sites. It was the first pharmacologic intervention shown to extend life in an animal model of aging.

Study method

For 10 weeks the mice that model Alzheimer's disease were fed chow containing rapamycin. At the start of treatment the mice were 6 months old, roughly the age of young adults, but already exhibited indications of learning and memory deficits and brain lesions.

At the end of the 10 weeks, the mice were tested in a contraption called the Morris water maze, sort of a miniature swimming pool used to assess learning and memory in rodents. At the end of the behavioral tests, the brains of the mice were analyzed to determine the effects of rapamycin on the lesions that indicate Alzheimer's.

Promise remains to be determined

Rapamycin, a bacterial product first isolated in soil from the island Rapa Nui in the South Pacific, also is being tested in cancer research studies. Rapa Nui is commonly known as Easter Island and is distinguished by ancient monoliths with faces.

“While it remains to be determined whether our results obtained in mice could be translated in people, we are very excited as these findings may lead to a new therapeutic intervention to treat Alzheimer's,” Dr. Oddo said.

Co-authors, all from the UT Health Science Center San Antonio, are Antonella Caccamo, M.S.; Smita Majumder, M.S.; Arlan Richardson, Ph.D.; and Randy Strong, Ph.D. Dr. Richardson, professor of cellular and structural biology, is director of the Barshop Institute. Dr. Strong, professor of pharmacology, and Dr. Richardson are senior research career scientists with the South Texas Veterans Health Care System.

About the UT Health Science Center San Antonio

The University of Texas Health Science Center at San Antonio, one of the country's leading health sciences universities, ranks in the top 2 percent of all U.S. institutions receiving federal funding. Research and other sponsored program activity totaled a record $259 million in fiscal year 2009. The university's schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced 27,000 graduates. The $753 million operating budget supports six campuses in San Antonio, Laredo, Harlingen and Edinburg. For more information on the many ways “We make lives better®,” visit www.uthscsa.edu.